Zhang Xin-Yu, Xu Ji, Zhu Hua-Yuan, Wang Yan, Wang Li, Fan Lei, Wu Yu-Jie, Li Jian-Yong, Xu Wei
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
Cancer Sci. 2016 Oct;107(10):1471-1476. doi: 10.1111/cas.13020. Epub 2016 Sep 14.
Tumor microenvironment and host immunity are closely related to outcome in patients with mantle cell lymphoma (MCL). However, few researchers have focused on the prognostic value of peripheral blood lymphocyte subsets counts. The purpose of this study was to investigate the prognostic value of lymphocyte subsets and absolute monocyte counts. Sixty-eight patients were analyzed retrospectively. Absolute CD4 T cell counts (ACD4C), CD8 T cell counts, nature killer cell counts, and CD4/CD8 ratios were assessed by peripheral blood flow cytometry and correlated with clinical parameters and long-term outcomes. The median follow-up for all patients was 21 months and the median survival time was 44 months. The overall survival (OS) rate at 1, 3, and 5 years was 80%, 51%, and 41%, respectively. In our cohort, high absolute monocyte count, and low ACD4C and CD4/CD8 ratio were associated with unfavorable OS (P = 0.029, P = 0.027, and P = 0.045, respectively) by univariate analysis. Multivariate analysis indicated that low ACD4C was a significant predictor of unfavorable OS (P = 0.004) independent of the simplified MCL International Prognostic Index (P = 0.048) in patients treated with or without rituximab (P = 0.011). Low CD4 T cell counts proved to be a significant predictor of unfavorable OS in patients with MCL.
肿瘤微环境和宿主免疫与套细胞淋巴瘤(MCL)患者的预后密切相关。然而,很少有研究人员关注外周血淋巴细胞亚群计数的预后价值。本研究的目的是探讨淋巴细胞亚群和绝对单核细胞计数的预后价值。对68例患者进行回顾性分析。通过外周血流式细胞术评估绝对CD4 T细胞计数(ACD4C)、CD8 T细胞计数、自然杀伤细胞计数和CD4/CD8比值,并将其与临床参数和长期预后相关联。所有患者的中位随访时间为21个月,中位生存时间为44个月。1年、3年和5年的总生存率(OS)分别为80%、51%和41%。在我们的队列中,单因素分析显示,高绝对单核细胞计数、低ACD4C和低CD4/CD8比值与不良OS相关(P分别为0.029、0.027和0.045)。多因素分析表明,在接受或未接受利妥昔单抗治疗的患者中(P = 0.011),低ACD4C是不良OS的显著预测因素(P = 0.004),独立于简化的MCL国际预后指数(P = 0.048)。低CD4 T细胞计数被证明是MCL患者不良OS的显著预测因素。